Ao Wang

Ao Wang

Auto-generated profile, based on publicly available information

Ao Wang

Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2019 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
AWAo Wang
Ao Wang
YBYanping Bai
Yanping Bai

15 November 2022 in World Allergy Organization Journal
Verified
Journal Article
Open access
AWAo Wang
Ao Wang
YYYuhui Yun
Yuhui Yun
ZWZhihua Wen
Zhihua Wen
YGYingxia Gao
Yingxia Gao
SQShuzhen Qi
Shuzhen Qi
XYXu Yao
Xu Yao
Omalizumab is an effective treatment for chronic spontaneous urticaria (CSU) patients aged ≥12 years, but its efficacy in patients aged <12 years has not been fully documented. We evaluated the therapeutic efficacy and safety of omalizumab in Chinese CSU population across all age groups. To assess the efficacy and safety of omalizumab treatment against CSU in China. This study was a retrospective and observational study, and the clinical data of CSU patients treated with omalizumab from October 2018 to August 2021 were collected and analyzed. We enrolled 235 patients in this study, and 54.0% (n = 127/235) of patients were female. All patients received at least three injections of omalizumab treatment, and the mean treatment duration was 3.4 ± 1.0 months. At the end of week-12, 98.7% (n = 232/235) of patients responded to omalizumab, among which 91.1% (n = 214/235) achieved a complete response (CR). An excellent response to omalizumab treatment was observed across all ages. All patients aged <12 years (n = 26) achieved a CR at the end of week-12, and clinical improvement was maintained until treatment cessation. Eighty-seven patients received 3–9-month follow-up after the end of treatment, with a mean duration of 5.7 ± 2.0 months, and 17.2% (n = 15/87) patients experienced recurrence after discontinuing treatment. No factors associated with therapeutic response and recurrence to omalizumab treatment were found in this study. Omalizumab is a safe and efficacious therapy for CSU patients, including those aged <12 years. We recommend addition of omalizumab to the treatment regimen in CSU patients under 12 years of age. This study was registered in Chinese Clinical Trial Registry (www.chictr.org.cn, Registration number: ChiCTR2200056599).

2 June 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YZYuan Zhou
Yuan Zhou
XXXiaoqiang Xu
Xiaoqiang Xu
YLYang Liu
Yang Liu
AWAo Wang
Ao Wang
YLYang Luo
Yang Luo
XYXu Yao
Xu Yao

8 May 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SLShiqi Ling
Shiqi Ling
BXBeilei Xu
Beilei Xu
YLYang Luo
Yang Luo
XFXiaokai Fang
Xiaokai Fang
XLXiaochun Liu
Xiaochun Liu
XYXu Yao
Xu Yao

19 December 2023 in Cell Reports Medicine
Verified
Journal Article
Open access
XLXiaochun Liu
Xiaochun Liu
BXBeilei Xu
Beilei Xu
XXXiaoqiang Xu
Xiaoqiang Xu
ZWZhifeng Wang
Zhifeng Wang
YLYang Luo
Yang Luo
XYXu Yao
Xu Yao
Allergen-specific immunotherapy (AIT) has shown beneficial effects against atopic dermatitis (AD); however, the mechanisms and parameters underlying the efficacy of AIT remain unclear. Here, we report that the community structure and function of the oral and gut microbiota are changed in patients with AD undergoing AIT. Transplantation of fecal microbiota from patients who respond well to AIT improves AD-like dermatitis in mice. The abundance of Brevundimonas vesicularis in the gut of AD patients has been found to be positively correlated with disease severity and is decreased following AIT. Furthermore, we find that B. vesicularis from the oral cavity might ectopically colonize the gut of AD patients. In AD model mice, meanwhile, B. vesicularis promotes the skewing of the Treg/Th17 balance toward Th17 polarization and attenuates the efficacy of ovalbumin-specific immunotherapy. Our findings provide potential strategies for the optimization of AIT for AD via the modulation of the gut microbiota.

1 January 2021
Verified
Conference Paper
Open access
ZBZhenghao Bao
Zhenghao Bao
Yuhao ZhangYuhao Zhang
Yuhao Zhang
AWAo Wang
Ao Wang
HHHe Huang
He Huang
YXYuexin Xu
Yuexin Xu
JYJun Yu
Jun Yu